Literature DB >> 25572805

Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.

Cuixia Yang1, Linyan He, Pingqing He, Yiwen Liu, Wenjuan Wang, Yiqing He, Yan Du, Feng Gao.   

Abstract

Tumor-associated macrophages (TAMs) appear to be the major component in solid tumor microenvironment, which were reported to play an important role in tumor malignant progression. Recently, TAMs were reported to be associated with drug resistance in some types of solid tumor including breast cancer. However, how TAMs regulate breast tumor resistance remains unknown. In this study, THP-1 cells were stimulated with PMA and IL-4/IL-13 to form M2-like macrophages to study the role of TAMs on chemoresistance. Our results showed that TAMs and its supernatants significantly prevent breast tumor cells from apoptosis caused by paclitaxel. We also found that the high level of IL-10 secreted by TAMS was responsible for drug resistance of breast cancer. The possible TAMs-modulated drug resistance mechanism involved may be associated with elevation of bcl-2 gene expression and up-regulation of STAT3 signaling in tumor cells. Furthermore, the blockage of TAMs-derived IL-10 by neutralizing antibody resulted in attenuation of STAT3 activation and decrease of bcl-2 mRNA expression, consequently enhanced sensitivity of breast cancer cells. Our data suggested that TAMs might induce drug resistance through IL-10/STAT3/bcl-2 signaling pathway, providing possible new targets for breast tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25572805     DOI: 10.1007/s12032-014-0352-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

Authors:  S Alas; B Bonavida
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Authors:  Masahisa Jinushi; Shigeki Chiba; Hironori Yoshiyama; Kenkichi Masutomi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Hideo Yagita; Akinori Takaoka; Hideaki Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

Review 4.  Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.

Authors:  Rita A Mukhtar; Onouwem Nseyo; Michael J Campbell; Laura J Esserman
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

5.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Authors:  Tanaya Shree; Oakley C Olson; Benelita T Elie; Jemila C Kester; Alfred L Garfall; Kenishana Simpson; Katherine M Bell-McGuinn; Emily C Zabor; Edi Brogi; Johanna A Joyce
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

Review 6.  Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation.

Authors:  Alberto Mantovani; Antonio Sica; Paola Allavena; Cecilia Garlanda; Massimo Locati
Journal:  Hum Immunol       Date:  2009-02-21       Impact factor: 2.850

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 8.  Creating immune privilege: active local suppression that benefits friends, but protects foes.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

9.  Importance of direct macrophage-tumor cell interaction on progression of human glioma.

Authors:  Yoshihiro Komohara; Hasita Horlad; Koji Ohnishi; Yukio Fujiwara; Bing Bai; Takenobu Nakagawa; Shinya Suzu; Hideo Nakamura; Jun-ichi Kuratsu; Motohiro Takeya
Journal:  Cancer Sci       Date:  2012-10-26       Impact factor: 6.716

10.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authors:  Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

View more
  53 in total

Review 1.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

2.  Hypoxia inducible factor-1α/B-cell lymphoma 2 signaling impacts radiosensitivity of H1299 non-small cell lung cancer cells in a normoxic environment.

Authors:  Gang Wang; Liang Xiao; Fen Wang; Jing Yang; Li Yang; Ye Zhao; Wensen Jin
Journal:  Radiat Environ Biophys       Date:  2019-06-15       Impact factor: 1.925

3.  Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer.

Authors:  G Sun; L Sun; Y Liu; H Xing; K Wang
Journal:  Cancer Gene Ther       Date:  2017-03-31       Impact factor: 5.987

4.  A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative.

Authors:  Elnaz Sheikhpour; Parisa Noorbakhsh; Elnaz Foroughi; Soudabeh Farahnak; Rezvan Nasiri; Hossein Neamatzadeh
Journal:  Rep Biochem Mol Biol       Date:  2018-10

Review 5.  The emerging roles of macrophages in cancer metastasis and response to chemotherapy.

Authors:  Luis Rivera Sanchez; Lucia Borriello; David Entenberg; John S Condeelis; Maja H Oktay; George S Karagiannis
Journal:  J Leukoc Biol       Date:  2019-02-05       Impact factor: 4.962

6.  [Tumor-associated macrophages attenuate apoptosis-inducing effect of sorafenib in hepatoma cells by increasing autophagy].

Authors:  Fang Wei; Shiye Zong; Jing Zhou; Min Fan; Ying Wang; Xiu Cheng; Hao Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

7.  Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia.

Authors:  Manli Song; Ting Liu; Changrong Shi; Xiangzhong Zhang; Xiaoyuan Chen
Journal:  ACS Nano       Date:  2015-12-14       Impact factor: 15.881

Review 8.  Tumor-associated macrophages in cancers.

Authors:  W Hu; X Li; C Zhang; Y Yang; J Jiang; C Wu
Journal:  Clin Transl Oncol       Date:  2015-08-12       Impact factor: 3.405

9.  Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer.

Authors:  Juanjuan He; Pengwei Lv; Xue Yang; Yanli Chen; Chao Liu; Xinguang Qiu
Journal:  Tumour Biol       Date:  2016-01-13

10.  Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.

Authors:  Mengmeng Niu; Solange Valdes; Youssef W Naguib; Stephen D Hursting; Zhengrong Cui
Journal:  Mol Pharm       Date:  2016-04-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.